| Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma A Vacca, D Ribatti, M Presta, M Minischetti, M Iurlaro, R Ria, A Albini, ... Blood, The Journal of the American Society of Hematology 93 (9), 3064-3073, 1999 | 793 | 1999 |
| Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo D Ribatti, M Presta, A Vacca, R Ria, R Giuliani, P Dell’Era, B Nico, ... Blood, The Journal of the American Society of Hematology 93 (8), 2627-2636, 1999 | 699 | 1999 |
| Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple … A Palumbo, S Bringhen, D Rossi, M Cavalli, A Larocca, R Ria, M Offidani, ... J clin Oncol 28 (34), 5101-5109, 2010 | 510 | 2010 |
| Efficacy and safety of once-weekly bortezomib in multiple myeloma patients S Bringhen, A Larocca, D Rossi, M Cavalli, M Genuardi, R Ria, S Gentili, ... Blood, The Journal of the American Society of Hematology 116 (23), 4745-4753, 2010 | 483 | 2010 |
| Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial A Palumbo, S Bringhen, AM Liberati, T Caravita, A Falcone, V Callea, ... Blood, The Journal of the American Society of Hematology 112 (8), 3107-3114, 2008 | 449 | 2008 |
| Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. A Palumbo, M Cavo, S Bringhen, E Zamagni, A Romano, F Patriarca, ... Journal of Clinical Oncology 29, 986-993, 2011 | 378 | 2011 |
| Antiangiogenesis is produced by nontoxic doses of vinblastine A Vacca, M Iurlaro, D Ribatti, M Minischetti, B Nico, R Ria, A Pellegrino, ... Blood, The Journal of the American Society of Hematology 94 (12), 4143-4155, 1999 | 349 | 1999 |
| Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a … F Gay, S Oliva, MT Petrucci, C Conticello, L Catalano, P Corradini, ... The lancet oncology 16 (16), 1617-1629, 2015 | 335 | 2015 |
| Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients F Gay, A Larocca, P Wijermans, F Cavallo, D Rossi, R Schaafsma, ... Blood, The Journal of the American Society of Hematology 117 (11), 3025-3031, 2011 | 331 | 2011 |
| Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma D Ribatti, A Vacca, B Nico, F Quondamatteo, R Ria, M Minischetti, ... British Journal of Cancer 79 (3), 451-455, 1999 | 302 | 1999 |
| Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple … A Palumbo, S Bringhen, A Larocca, D Rossi, F Di Raimondo, V Magarotto, ... Journal of Clinical Oncology 32 (7), 634-640, 2014 | 244 | 2014 |
| Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials S Bringhen, MV Mateos, S Zweegman, A Larocca, AP Falcone, A Oriol, ... Haematologica 98 (6), 980, 2013 | 243 | 2013 |
| Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program L Pagano, C Girmenia, L Mele, P Ricci, ME Tosti, A Nosari, M Buelli, ... haematologica 86 (8), 862-870, 2001 | 243* | 2001 |
| Characterization of mitochondrial and extra-mitochondrial oxygen consuming reactions in human hematopoietic stem cells: novel evidence of the occurrence of NAD (P) H oxidase … C Piccoli, R Ria, R Scrima, O Cela, A D'Aprile, D Boffoli, F Falzetti, ... Journal of Biological Chemistry 280 (28), 26467-26476, 2005 | 239 | 2005 |
| Endothelial cells in the bone marrow of patients with multiple myeloma A Vacca, R Ria, F Semeraro, F Merchionne, M Coluccia, A Boccarelli, ... Blood 102 (9), 3340-3348, 2003 | 234 | 2003 |
| A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma A Vacca, R Ria, D Ribatti, F Semeraro, V Djonov, F Di Raimondo, ... Haematologica 88 (2), 176-185, 2003 | 197 | 2003 |
| Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B‐cell non‐Hodgkin's lymphomas D Ribatti, A Vacca, A Marzullo, B Nico, R Ria, L Roncali, F Dammacco International Journal of Cancer 85 (2), 171-175, 2000 | 184 | 2000 |
| Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas A Vacca, D Ribatti, L Ruco, F Giacchetta, B Nico, F Quondamatteo, R Ria, ... British Journal of Cancer 79 (5), 965-970, 1999 | 170 | 1999 |
| Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma C Scavelli, B Nico, T Cirulli, R Ria, G Di Pietro, D Mangieri, A Bacigalupo, ... Oncogene 27 (5), 663-674, 2008 | 167 | 2008 |
| Angiogenesis extent and expression of matrix metalloproteinase-2 and-9 correlate with upgrading and myometrial invasion in endometrial carcinoma. M Iurlaro, G Loverro, A Vacca, G Cormio, D Ribatti, M Minischetti, R Ria, ... European journal of clinical investigation 29 (9), 793-801, 1999 | 165 | 1999 |
